샘플 요청 목록

 카트 문의
시장보고서
상품코드
1739229

세계의 재발 또는 난치성 미만성대세포형 B세포 림프종 시장

Relapsed or Refractory Diffuse Large B Cell Lympho
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 294 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 재발 또는 난치성 미만성대세포형 B세포 림프종 시장은 2030년까지 18억 달러에 이를 전망

2024년에 15억 달러로 추정되는 재발 또는 난치성 미만성대세포형 B세포 림프종 세계 시장은 2024-2030년간 CAGR 2.9%로 성장하여 2030년에는 18억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Monjuvi는 CAGR 1.7%를 나타내고, 분석 기간 종료시에는 4억 5,640만 달러에 이를 것으로 예측됩니다. XPOVIO 부문의 성장률은 분석 기간에 CAGR 3.9%로 추정됩니다.

미국 시장은 4억 800만 달러로 추정, 중국은 CAGR 5.3%로 성장 예측

미국의 재발 또는 난치성 미만성대세포형 B세포 림프종 시장은 2024년에 4억 800만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 3억 4,300만 달러 규모에 이를 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 5.3%로 추정됩니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 분석 기간중 CAGR은 각각 1.2%와 2.2%를 보일 것으로 예측됩니다. 유럽에서는 독일이 CAGR 1.6%를 보일 것으로 예측됩니다.

세계의 '재발 또는 난치성 미만성대세포형 B세포 림프종(R/R DLBCL)' 시장 - 주요 동향과 촉진요인 정리

재발성/불응성 미만성 거대 B세포 림프종(R/R DLBCL)이 암 분야에서 여전히 큰 문제인 이유는 무엇일까요?

미만성 대세포 B세포 림프종(DLBCL)은 비호지킨림프종 중 가장 흔한 아형으로 전 세계 비호지킨림프종 환자의 약 30%를 차지하며, R-CHOP(화학요법 및 리툭시맙)과 같은 1차 치료로 상당수의 환자에서 관해가 가능하지만, 약 30-40%는 재발하거나 40%는 재발을 경험하거나 1차 치료에 반응하지 않고 재발 또는 불응성(R/R) DLBCL로 분류됩니다. 이 환자군은 예후가 좋지 않으며, 치료 옵션이 제한되어 있습니다. 질병의 이질성은 종종 MYC, BCL2, BCL6 재배열과 같은 유전자 이상에 의해 발생하여 치료 전략을 복잡하게 만듭니다. 고용량 화학요법 후 자가 줄기세포 이식과 같은 전통적인 치료법은 나이와 합병증으로 인해 적합하지 않은 경우가 많아 치료 공백이 남아있습니다. 이 분야의 미충족 의료 수요는 매우 커서 표적치료와 세포성 면역치료 모두에서 지속적인 연구와 혁신을 촉진하고 있습니다.

혁신적인 치료법은 R/R DLBCL 환자의 전망을 어떻게 바꾸고 있는가?

획기적인 치료법은 R/R DLBCL의 표준 치료를 재정의하고, 불치병으로 여겨지던 환자에게 새로운 희망을 가져다주고 있습니다. 가장 영향력 있는 혁신적 치료법은 키메라 항원 수용체 T 세포(CAR-T) 요법으로, 악티카부타진 실로로이셀과 티사겐 레클로로이셀 등이 있습니다. 이러한 개별화 세포치료는 환자 자신의 면역세포를 재프로그래밍하여 림프종 세포를 인식하고 죽이도록 합니다. 이와 함께, 폴라투주맙 베도틴과 같은 항체 약물 복합체(ADC)와 글로피타맙과 같은 이중 특이성 항체가 높은 효능과 관리 가능한 독성 프로파일을 가진 시판 가능한 대안으로 떠오르고 있습니다. 저분자 억제제도 활발히 연구되고 있습니다. 이러한 치료법 개발은 환자의 질병 분자 프로파일에 따라 맞춤형 치료가 이루어지고, 과거 치명적이었던 재발이 관리 가능한 만성 질환이나 완치 가능성이 있는 질환으로 변화하는 정밀 종양학(Precision Oncology)의 광범위한 추세를 반영하고 있습니다.

어떤 의료 및 시장 역학이 이러한 치료법의 채택을 형성하고 있는가?

R/R형 DLBCL 치료제 시장은 규제, 헬스케어 시스템, 지불자의 역학이 수렴하면서 형성되고 있으며, FDA 및 EMA와 같은 규제 기관은 일부 첨단 치료제에 조기 승인 및 획기적 치료제 지정을 통해 신속한 접근과 추가 연구개발에 대한 인센티브를 부여하고 있습니다. 하지만, 특히 CAR-T 치료제는 치료비용이 비싸기 때문에 상환 모델과 접근성을 둘러싼 논쟁이 벌어지고 있습니다. 지불자는 이러한 고비용 치료법을 채택하는 데 따른 재정적 위험을 관리하기 위해 결과 기반 계약이나 가치 기반 치료 계약을 평가했습니다. 의료 서비스 제공업체들은 CAR-T와 같은 복잡한 치료법을 시행하기 위해 전문센터와 다학제 팀을 필요로 하는 인프라 및 교육에 투자하고 있습니다. 한편, 제약사들은 확장성을 개선하고 치료 지연을 줄이기 위해 제조 시간을 단축하고 기성품 형식으로 차세대 CAR-T를 개발하고 있습니다. 환자 지원 단체와 디지털 플랫폼도 인지도를 높이고, 접근성 프로그램을 지원하며, 환자를 임상시험에 참여시키는 역할을 하고 있습니다.

재발 및 난치성 DLBCL 시장의 성장은 획기적인 면역요법, 정밀 종양학 동향, 복잡한 생물학적 제제를 위한 인프라 확충이 견인하고 있습니다.

재발성 및 불응성 DLBCL 시장의 성장은 여러 가지 복합적인 요인에 의해 주도되고 있습니다. 첫째, 차세대 면역치료, 특히 CAR-T 세포치료제, ADC, 이중 특이성 항체 등 차세대 면역치료제의 등장으로 선택지가 제한된 환자들의 생존 예후를 크게 바꾸고 있습니다. 둘째, 유전체 프로파일링과 동반 진단을 가능하게 하는 정밀의료의 도입으로 종양 전문의는 고위험 DLBCL 하위 집합을 식별하고 표적 치료와 매칭할 수 있게 되었습니다. 셋째, 자동화 및 분산형 CAR-T 생산 모델을 포함한 바이오의약품 제조의 개선으로 첨단 치료법에 대한 접근성과 확장성이 향상되고 있습니다. 넷째, 병원과 종양센터의 세포치료실과 전문 수액 시설에 대한 투자 확대로 복잡한 생물학적 제제를 안전하고 효율적으로 투여하는 것이 더 쉬워지고 있습니다. 또한, 헬스케어 정책, 신속한 승인, 임상시험 네트워크의 확대는 혁신적인 치료법의 신속한 시장 출시를 촉진하고 있습니다. 마지막으로, 기존 화학요법을 대체할 수 있는 더 오래 지속되고 독성이 적은 치료법에 대한 환자들의 요구는 의사와 의료비 지불자가 진화하는 표준 치료의 일환으로 새로운 치료법을 채택하도록 유도하고 있습니다.

부문

약제 유형(Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, 기타 약제 유형), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 예(총 48개사)

  • AbbVie Inc.
  • Adaptive Biotechnologies Corp.
  • ADC Therapeutics SA
  • Bristol Myers Squibb
  • Cellular Biomedicine Group Inc.
  • Eagle Pharmaceuticals, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hoffmann-La Roche AG
  • IMV Inc.
  • Incyte Corporation
  • Janssen Biotech, Inc.
  • Karyopharm Therapeutics
  • Merck & Co., Inc.
  • MorphoSys U.S. Inc.
  • Novartis AG
  • Overland Pharmaceuticals
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수익원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월: 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월: 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석 :

미국 <>& 중국 <>& 멕시코 <>& 캐나다 <>&EU <>& 일본 <>& 인도 <>& 기타 176개국

업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

LSH 25.06.17

Global Relapsed or Refractory Diffuse Large B Cell Lympho Market to Reach US$1.8 Billion by 2030

The global market for Relapsed or Refractory Diffuse Large B Cell Lympho estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monjuvi, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$456.4 Million by the end of the analysis period. Growth in the XPOVIO segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$408.0 Million While China is Forecast to Grow at 5.3% CAGR

The Relapsed or Refractory Diffuse Large B Cell Lympho market in the U.S. is estimated at US$408.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$343.0 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global “Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)” Market - Key Trends & Drivers Summarized

Why Is Relapsed or Refractory DLBCL a Persistent Challenge in Oncology?

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30% of all NHL cases worldwide. While first-line therapies such as R-CHOP (rituximab with chemotherapy) achieve remission in a significant number of patients, about 30-40% experience relapse or do not respond to initial treatment-classified as relapsed or refractory (R/R) DLBCL. This patient subgroup faces a poor prognosis, with limited curative options. The heterogeneity of the disease, often driven by genetic abnormalities like MYC, BCL2, and BCL6 rearrangements, complicates treatment strategies. Conventional salvage therapies such as high-dose chemotherapy followed by autologous stem cell transplant are often unsuitable due to age or comorbidities, leaving a therapeutic gap. The unmet clinical need in this space is immense, spurring ongoing research and innovation in both targeted and cellular immunotherapies.

How Are Innovative Therapies Transforming the Outlook for R/R DLBCL Patients?

Breakthrough therapies are redefining the standard of care for R/R DLBCL and bringing renewed hope to patients who were previously considered incurable. Among the most impactful innovations are chimeric antigen receptor T-cell (CAR-T) therapies, including axicabtagene ciloleucel and tisagenlecleucel, which have shown substantial complete remission rates even in heavily pre-treated patients. These personalized cell-based therapies reprogram a patient's own immune cells to recognize and kill lymphoma cells. In parallel, antibody-drug conjugates (ADCs) like polatuzumab vedotin and bispecific antibodies such as glofitamab are emerging as viable off-the-shelf options with high efficacy and manageable toxicity profiles. Small molecule inhibitors targeting key pathways such as BTK, PI3K, and BCL2 are also under active investigation. The development of these therapies reflects a broader trend toward precision oncology, where treatments are increasingly tailored to the molecular profile of the patient’s disease, transforming once-fatal relapses into manageable chronic conditions or potential cures.

Which Healthcare and Market Dynamics Are Shaping the Adoption of These Therapies?

The R/R DLBCL treatment market is being shaped by a convergence of regulatory, healthcare system, and payer dynamics. Regulatory bodies such as the FDA and EMA have granted accelerated approvals and breakthrough designations to several advanced therapies, fast-tracking access and incentivizing further R&D. However, high treatment costs, especially for CAR-T therapies, have sparked debate over reimbursement models and accessibility. Payers are increasingly evaluating outcomes-based contracts and value-based care agreements to manage the financial risk of adopting these high-cost therapies. Healthcare providers are also investing in infrastructure and training for administering complex treatments like CAR-T, which require specialized centers and multidisciplinary teams. Meanwhile, pharmaceutical companies are developing next-generation CAR-Ts with reduced manufacturing times and off-the-shelf formats to improve scalability and reduce treatment delays. Patient advocacy groups and digital platforms are also playing a role by increasing awareness, supporting access programs, and connecting patients to clinical trials.

The Growth in the Relapsed or Refractory DLBCL Market Is Driven by Breakthrough Immunotherapies, Precision Oncology Trends, and Infrastructure Expansion for Complex Biologics

The growth in the relapsed or refractory DLBCL market is driven by several interlinked factors. Chief among them is the rise of next-generation immunotherapies-particularly CAR-T cell therapies, ADCs, and bispecific antibodies-which are transforming survival outcomes for patients with limited options. Secondly, the adoption of precision medicine, enabled by genomic profiling and companion diagnostics, is allowing oncologists to identify high-risk DLBCL subsets and match them with targeted therapies. Thirdly, improvements in biopharmaceutical manufacturing, including automation and decentralized CAR-T production models, are enhancing the accessibility and scalability of advanced treatments. Fourthly, growing investments by hospitals and oncology centers in cell therapy units and specialized infusion facilities are making it easier to deliver complex biologics safely and efficiently. Additionally, supportive healthcare policies, fast-track approvals, and expanded clinical trial networks are helping bring innovative therapies to market faster. Lastly, patient demand for more durable and less toxic alternatives to traditional chemotherapy is pushing physicians and payers to adopt these novel therapies as part of an evolving standard of care.

SCOPE OF STUDY:

The report analyzes the Relapsed or Refractory Diffuse Large B Cell Lympho market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Other Drug Types); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Adaptive Biotechnologies Corp.
  • ADC Therapeutics SA
  • Bristol Myers Squibb
  • Cellular Biomedicine Group Inc.
  • Eagle Pharmaceuticals, Inc.
  • Genmab A/S
  • Gilead Sciences, Inc.
  • Hoffmann-La Roche AG
  • IMV Inc.
  • Incyte Corporation
  • Janssen Biotech, Inc.
  • Karyopharm Therapeutics
  • Merck & Co., Inc.
  • MorphoSys U.S. Inc.
  • Novartis AG
  • Overland Pharmaceuticals
  • Pfizer Inc.
  • Regeneron Pharmaceuticals
  • Takeda Pharmaceutical Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Relapsed or Refractory Diffuse Large B Cell Lympho - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Non-Hodgkin Lymphoma Drives Demand for Second-Line Treatment Options
    • Breakthrough Approvals in CAR-T Cell Therapy Expand Advanced Treatment Availability
    • Pipeline Development of Bispecific Antibodies Spurs Competitive Innovation
    • Shift Toward Personalized Oncology Enhances Role of Genomic Profiling in R/R DLBCL Treatment
    • Increased Clinical Trial Activity Across Immunotherapy Classes Expands Market Opportunities
    • Regulatory Fast Track Designations Accelerate Access to Novel Drug Classes
    • Adoption of Antibody-Drug Conjugates (ADCs) Strengthens Outcomes in Refractory Patients
    • Growing Hospital Investment in Cell Therapy Infrastructure Supports CAR-T Commercialization
    • Rise in Patient Assistance Programs Enhances Access to High-Cost Treatment Modalities
    • Use of Companion Diagnostics Improves Patient Stratification and Therapeutic Precision
    • Strategic Pharma Collaborations Fuel Co-Development of Targeted Agents
    • Expansion of Academic Research into Resistance Mechanisms Spurs Innovation
    • Shift from Chemotherapy-Dependent Approaches to Immuno-Oncology Alters Treatment Landscape
    • Global Expansion of Cell Therapy Manufacturing Capacity Increases Access in Emerging Markets
    • Increasing Physician Familiarity with Multi-Line Treatment Protocols Improves Uptake
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Relapsed or Refractory Diffuse Large B Cell Lympho Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monjuvi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for XPOVIO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Polivy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Kymriah by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Yescarta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제